Correlation Between Sunmax Biotechnology and Medigen Biotechnology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Sunmax Biotechnology and Medigen Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sunmax Biotechnology and Medigen Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Sunmax Biotechnology Co and Medigen Biotechnology, you can compare the effects of market volatilities on Sunmax Biotechnology and Medigen Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sunmax Biotechnology with a short position of Medigen Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sunmax Biotechnology and Medigen Biotechnology.

Diversification Opportunities for Sunmax Biotechnology and Medigen Biotechnology

-0.67
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Sunmax and Medigen is -0.67. Overlapping area represents the amount of risk that can be diversified away by holding Sunmax Biotechnology Co and Medigen Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Medigen Biotechnology and Sunmax Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sunmax Biotechnology Co are associated (or correlated) with Medigen Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Medigen Biotechnology has no effect on the direction of Sunmax Biotechnology i.e., Sunmax Biotechnology and Medigen Biotechnology go up and down completely randomly.

Pair Corralation between Sunmax Biotechnology and Medigen Biotechnology

Assuming the 90 days trading horizon Sunmax Biotechnology Co is expected to generate 0.55 times more return on investment than Medigen Biotechnology. However, Sunmax Biotechnology Co is 1.82 times less risky than Medigen Biotechnology. It trades about -0.08 of its potential returns per unit of risk. Medigen Biotechnology is currently generating about -0.27 per unit of risk. If you would invest  27,850  in Sunmax Biotechnology Co on September 24, 2024 and sell it today you would lose (450.00) from holding Sunmax Biotechnology Co or give up 1.62% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Sunmax Biotechnology Co  vs.  Medigen Biotechnology

 Performance 
       Timeline  
Sunmax Biotechnology 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Sunmax Biotechnology Co are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly stable basic indicators, Sunmax Biotechnology is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.
Medigen Biotechnology 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Medigen Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Sunmax Biotechnology and Medigen Biotechnology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Sunmax Biotechnology and Medigen Biotechnology

The main advantage of trading using opposite Sunmax Biotechnology and Medigen Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sunmax Biotechnology position performs unexpectedly, Medigen Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medigen Biotechnology will offset losses from the drop in Medigen Biotechnology's long position.
The idea behind Sunmax Biotechnology Co and Medigen Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Other Complementary Tools

Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Global Correlations
Find global opportunities by holding instruments from different markets
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories